Alamar Biosciences, Inc. ALMR
- Market cap
- $2.4B
- P/E
- 0.0×
Follow ALMR
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | 222 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | 25 | 74 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | 34.23% | 56.20% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | — | (47) | (29) |
EBT
|
|||
| — | — | — | — | — | — | — | — | (187.18%) | (39.29%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (47) | (30) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 1 | 4 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 2.39 | 6.43 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (4.47) | (2.58) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (5.25) | (4.64) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.28) | (0.47) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (5.53) | (5.11) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 9.65 | 6.59 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 11 | 12 |
Shares
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | (2.64) | (2.64) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | — | (55) | (54) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | (3) | (5) |
Capex
|
|||
| — | — | — | — | — | — | — | — | (58) | (59) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 90 | 71 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | 10 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | (80) | (20) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 102 | 76 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (20.60%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | (141.04%) | (35.06%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 20.40% |
ROE
|
|||
Alamar Biosciences, Inc. (ALMR) key facts
- Alamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024.
- Alamar Biosciences, Inc. reported a net loss of $29.8 million, or a loss of $2.58 per share, for fiscal 2025.
- As of September 25, 2026, ALMR traded at $32.80, a market capitalization of $2.4 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 22.7× sales.
- Return on equity was 20.4% and debt-to-equity 0.03.
Alamar Biosciences, Inc. (ALMR) Latest News
24 Sep
Lancet Neurology reports a longitudinal study in real-world practice showing markedly different biological responses during lecanemab treatment in early symptomatic Alzheimer’s disease. Using Alamar’s NULISAseq CNS 120 panel to assay 130 plasma proteins, researchers analyzed 2,385 samples from 1,967 participants (including treated patients and untreated controls). Among 197 treated with lecanemab, 34 biomarkers changed with infusion count, and brain-derived tau consistently outperformed blood-based tau in distinguishing patients from controls. Amyloid-clearing biomarkers tracked separate biology from those linked to cognitive decline, helping explain why amyloid clearance does not uniformly yield clinical benefit. The study underscores ultra-high-sensitivity, multi-protein profiling as essential to understanding treatment response, illustrating why measuring a single biomarker is insufficient. Demonstrates need for ultra-high-sensitivity, multi-biomarker proteomics in real-world Alzheimer’s treatment monitoring, potentially expanding use of Alamar's platform.
17 Aug
Alamar Biosciences held Q2 2026 earnings call covering quarterly financial results, operational updates and forward outlook. Quarterly earnings details and guidance directly shape near-term valuation and investor positioning.
11 Aug
Alamar Biosciences Inc (ALMR) posted 82% revenue growth in Q2 2026 fueled by 147% expansion per earnings call highlights. 82% revenue surge reflects major financial gains that will likely shift investor sentiment and company trajectory.
10 Aug
Alamar Biosciences reported second quarter 2026 financial results and issued 2026 revenue guidance. Quarterly results plus full-year revenue guidance typically move valuations and sentiment for small-cap biotech firms.
Alamar Biosciences Q2 earnings call highlighted financial performance, operational updates and forward outlook. Q2 earnings updates may influence short-term market sentiment without fundamentally altering long-term trajectory.
Alamar Biosciences expands global partnership with Alzheimer’s Disease Data Initiative and Gates Ventures. Expanded partnership may strengthen Alamar Biosciences research collaborations and visibility in Alzheimer's space.
28 Jul
Alamar Biosciences launches NULISAseq Immune 340 Panel for comprehensive profiling of the immune proteome. New product launch expands Alamar's immune profiling offerings and strengthens its market position in proteomics.
Alamar Biosciences launches NULISAseq Immune 340 Panel for comprehensive profiling of the immune proteome. Major new product launch in immune proteomics expands portfolio and strengthens competitive positioning.
23 Jul
ALZpath broadens strategic agreement with Alamar Biosciences to advance clinical diagnostics for Alzheimer's disease. Expanded ALZpath partnership directly strengthens Alamar's Alzheimer's diagnostics development and competitive positioning.
13 Jul
Alamar Biosciences gains traction from rising interest in its Alzheimer's work, boosting visibility and investor attention around core diagnostic efforts. Alzheimer's buzz signals major strategic relevance that can shift investor sentiment and company trajectory.
Alamar Biosciences partners with leading research universities to launch a national initiative advancing blood-based biomarkers for neurodegenerative diseases. University partnerships and national biomarker initiative launch strengthen Alamar's research position and long-term prospects in neurodegenerative diagnostics.
Alamar Biosciences partners with leading research universities to launch national initiative advancing blood-based biomarkers for neurodegenerative diseases. Partnership launches major national initiative in core biomarker technology directly strengthening competitive position in neurodegenerative diagnostics.
10 Jul
Alamar Biosciences NULISA data featured in over 140 scientific presentations at AAIC 2026, advancing blood-based Alzheimer’s biomarker profiling. High-visibility conference exposure strengthens credibility and accelerates adoption of core biomarker technology in key therapeutic area.
Alamar Biosciences NULISA data appears in more than 140 presentations at AAIC 2026, advancing blood-based Alzheimer’s biomarker profiling. Extensive conference exposure for NULISA technology boosts Alzheimer's biomarker research profile and potential market adoption.
7 Jul
Alamar Biosciences launches the first multiplexed blood-based immunoassay for eMTBR-Tau, a key biomarker in Alzheimer’s disease research. Launch of novel multiplexed immunoassay for major Alzheimer’s biomarker advances core product portfolio and market reach.
Alamar Biosciences launches the first multiplexed blood-based immunoassay for eMTBR-Tau, a key biomarker in Alzheimer’s disease research. Novel immunoassay launch strengthens Alamar's position in Alzheimer's biomarker market with potential revenue growth.
2 Jun
Alamar Biosciences achieves compatibility of home-collected fingerstick samples with its ultra high-sensitivity multiplex proteomics platform. Home-collected sample compatibility expands market reach and adoption for Alamar proteomics technology.
8 May
Alamar Biosciences reported first quarter 2026 financial results. Quarterly financial results can shift near-term investor views on performance metrics.
20 Apr
Alamar Biosciences lists on NASDAQ as precision proteomics leader. NASDAQ listing delivers major capital access and market visibility to Alamar Biosciences.